medigraphic.com
Academia Mexicana de Neurología, A.C.

2013, Number 6

<< Back Next >>

Rev Mex Neuroci 2013; 14 (6)

Experience with the use of rivastigmine in patients with Parkinson’s disease and cognitive disorders

Ferrer O, Soto MC, Ferrer Y, Ferrer A, Ferrer Y, Hernández A, Pachano F, Muñoz-Cabas D, Noguera O

Language: Spanish
References: 32
Page: 328-334
PDF size: 167.28 Kb.


ABSTRACT

Introduction: Parkinson’s disease is a degenerative disorder of the central nervous system with a prevalence of approximately 1% in people over 65 years and slightly more common in men than in women and in Caucasians than in the other.
Objectve: To determine the effectiveness of rivastigmine of cognitive disorders in patients with Parkinson’s disease.
Methods: Descriptive study based on clinical experience in a sample of 36 patients with Parkinson’s disease attending the Neurology Clinic of the University Hospital of Maracaibo, Venezuela, during the period January to June 2010, divided into two groups, the first consisting of 18 patients treated with rivastigmine in patches of 10 cm2 for 24 weeks, and the second, 18 patients who were given a vitamin tablet. They were administered the MMSE or Folstein Scale (MMSE) before and after the procedure.
Results: The distribution in terms of age, sex, duration of disease, MMSE score (MM) and the UPDRS-III were statistically similar. Initially the MM was less than 24 points, indicating moderate or severe cognitive impairment in patients evaluated in both groups. It was noted that mean age, the duration of disease and UPDRS-III total score were statistically similar in the 2 groups of patients at study in patients treated with rivastigmine. When comparing the results of the MMSE at the end of the study, patients treated with rivastigmine showed higher mean score orientation, concentration and calculation and memory, with statistically significant differences (p ‹ 0.01, p ‹ 0.01 and p ‹ 0.0004).
Conclusions:That transdermal rivastigmine is a useful alternative in the management of cognitive disorders of patients with Parkinson’s disease. Because this is a descriptive study, these results should be interpreted with caution.


REFERENCES

  1. Ostrosky F. Características neuropsicológicas de la enfermedad de Parkinson. Rev Neurol 2000; 30: 788-96.

  2. Iranzo A. Parkinson disease and sleep: sleep-wake changes in the premotor stage of Parkinson disease; impaired olfaction and other prodromal features. Curr Neurol Neurosci Rep 2013: 13: 373-85.

  3. Kulisevsky J, Luquin M, Arbelo J, Burguera J, Carrillo F, Castro A, et al. Advanced Parkinson’s disease: Clinical characteristics and treatment. Part II. Neurologia 2013; 20: 118-7.

  4. Pascual A, Press D. Trastornos cognitivos y comportamentales en la enfermedad de Parkinson. Rev Neurol 1999; 29: 15-27.

  5. Moustafa A, Krishna R, Eissa A, Hewedi D. Factors underlying probabilistic and deterministic stimulus-response learning performance in medicated and unmedicated patients with Parkinson’s disease. Neuropsychology 2013; 27: 498-510.

  6. Fernández R, Pagonabarraga J, Martínez S, Pascual B, Campolongo A, Kulisevsky J. Parkinson’s disease-cognitive rating scale: Psychometrics for mild cognitive impairment. Mov Disord 2013; 19: 1002-8.

  7. Cummings J. Depression and Parkinson’s disease: A review. Am J Psychiatry 1992; 149: 443-54.

  8. Kulkantrakorn K, Tanyakitpisal P, Towanabut S, Dejthevaporn C, Rangseekajee P, Pongpakdee S, et al. Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand. Psychogeriatrics 2013; 13: 1-8.

  9. Cassinelli D, Santibáñez R. Relación entre manifestaciones motoras y deterioro cognitivo en la enfermedad de Parkinson. Rev ecuat neurol 2004; 13: 123-9.

  10. Sánchez J, Sayago A. Variables asociadas al deterioro cognitivo en la enfermedad de Parkinson. Rev Neurol 2001; 32: 107-111.

  11. Errea J, Ara B. Deterioro cognoscitivo en la enfermedad de Parkinson: factores de riesgo asociado. Rev Neurol 1999; 28: 439-443.

  12. Alonso E, Esteban E, Trujillo C, Lara G, Roussó T, Cordero A. Alteraciones específicas de la atención en estadios tempranos de la enfermedad de Parkinson. Rev Neurol 2003; 36: 1015-8.

  13. Agüera L, Ramos M, Gobartt A. Estudio comparativo de la efectividad y tolerabilidad de un procedimiento de escalado lento de dosis de rivastigmina en pacientes con demencia tipo Alzheimer leve o moderada: estudio SCALEX. Rev Neurol 2008; 46: 517-24.

  14. Farlow M. Update on Rivastigmine. Neurologist 2003; 9: 230-4.

  15. Blesa R, Boada M, Martínez C, Gil D, Almagro D, Gobartt A. Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer. Neurol 2011; 26: 145-51.

  16. Siddiqui M, Waqstaff A. Rivastigmine: in Parkinson’s disease dementia CNC Drugs 2006; 20: 739-47.

  17. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind placebo-controlled international study. Lancet 2000; 356: 2031-6.

  18. Wesnes K, McKeith I, Edgar C, Emre M. Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65: 1654-6.

  19. Wesnes K. Rivastigmine tartrate with a focus on dementia associated with Parkinson’s disease. Drugs Today 2007; 43: 349-59.

  20. Kordower J, Olanow C, Dodiya H, Chu Y, Beach T, Adler C, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013; 136: 2419-31.

  21. Grinberg L, Rub U, Alho A, Heisen H. Braistem pathology and nonmotor symptoms in PD. J Neurol SCI 2010; 15: 81-8.

  22. Emre M. Treatment of Dementia associated with Parkinson’s disease. Parkinsonism Real Dosird 2007; 13: S457-61.

  23. Aarsland D. Kurt M. The Epidemiology of Dementia associated with Parkinson disease J Neurlol Sci 2010; 15: 18-22.

  24. Micheli F. Enfermedad de Parkinson. En: Micheli F, Nogués MA, Asconapé J, Fernández M, Biller J (eds.). Tratado de Neurología Clínica. 1ra Ed. Panaméricana; 2002, p. 501-30.

  25. Schmitt F, Farlow M, Meng X, Tekin J. Efficacy of Rivastigmine on executive funtion in patients with Parkinson’s disease dementia. CNC Neurosci Ther 2010; 16: 330-6.

  26. Poewe W, Wlters E, Emre M, Onofri M, Hsu C, Tekin S, et al. Expres Investigators. Mov Disord 2006; 21: 456-61.

  27. Rodríguez I, Cabo I, Bellas P, Sebriant E. Trastornos cognitivos y neuropsiquiátricos en la enfermedad de Parkinson, Rev Neurol 2010; 50: 533-9.

  28. Cummings J, Winblad B. Un parche de rivastigmina para el tratamiento de la enfermedad de Alzheimer y la demencia con enfermedad de Parkinson. Expertos Neurother Rev 2007; 7: 1457-63.

  29. Chitnis S, J Rao. Rivastigmina en la demencia de la enfermedad de Parkinson. Drogas Metab Toxicol 2009; 5: 941-55.

  30. Almaraz C, Conductor B, Woodruff K, Caselli B, Demaerschalk A, Caviedes D. La eficacia de rivastigmina para los síntomas cognitivos en la enfermedad de Parkinson con demencia. Neurologist 2009; 15: 234-7.

  31. Moretti R, Torre P, Volotti C, Antonello RM, Pizzolato G. Rivastigmine and Parkinson dementia complex. Expert Opin Pharmacother 2007; 8: 817-29.

  32. Darreh S, Jelic V. La seguridad y tolerabilidad del tratamiento con rivastigmina transdérmica y oral en la enfermedad de Alzheimer y la demencia con enfermedad de Parkinson. Expert Opinon Drug Safetly 2010; 9: 167-76.




2020     |     www.medigraphic.com